Das Lektin der Mistel als Immunmodulator: Effektorwirkung auf ß-Endorphin-und Zytokinfreisetzung bei Mammakarzinompatientinnen

Journal/Book: Dtsch. Zschr. Onkol. 26 (4), 103-108. 1994;

Abstract: The effects of therapeutical administration of an aqueous mistletoeextract standardized for galactoside-specific mistletoe lectin (ML-1) onthe plasma level of beta-endorphin, on the lymphocyte subpopulationcount (pan T-cells, helper/inducer T-cells, suppressor/cytotoxicT-cells, natural killer (NK) cells) as well as on the release ofcytokines in vitro by mononuclear immunocompetent cells from patientswith breast cancer (n = 36) has been examined. Regular subcutaneousinjections of the immunomodulatory optimum dose of ML-1 (1 ng per kg ofbody weight, twice per week, for 12 weeks) caused in the patients 1. asignificant increase of beta-endorphin (p<0.005) in the plasma, 2.enhancement of different subpopulations of T-lymphocytes and NK-cells inperipheral blood, 3. a distinct increase of the release of cytokines invitro (IL-2, IFN-gamma, TNF-alpha) by mononuclear immunocompetent cellsafter adequate stimulation. The release of beta-endorphin during themistletoe therapy seems to correlate with stabilization of well-beingand quality of life in tumor patients (female patients), while therelease of cytokines and the enhancement of defined lymphocytesubpopulations give proof of the immunoactive effect of the administeredmistletoe extract which has been standardized to ML-1.

Keyword(s): Medical:breast-carcinoma

Zurück | Weiter